Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
“BO W EL 550 mg 3 times daily in patients with nonconstipated IBS resulted in significantly more patients reporting adequate relief of global IBS symptoms and bloating during the first 4 weeks of follow-up.(58) Improvement in symptoms relative to placebo persisted for the 10-week follow-up period, even though a gradual…”
BackgroundSelf-citationThe gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.
(2015) · PubMed Central · Cited by 2,540
Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Obesity · doi:10.1002/oby.20461 · Cited by 1,650
“[388] Pimentel M, Lembo A, Chey WD, et al.”
BackgroundStress & the gut-brain axis: Regulation by the microbiome
Foster, J. A., Rinaman, L., & Cryan, J. F. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2017.03.001 · Cited by 1,150
“Many of the preclinical models of increased visceral pain are induced by applying a psychological or physical stressor that relate to factors known to predispose to IBS, a clinical disorder characterized by visceral hypersensitivity to pain (Mayer et al., 2001).”
InfluentialRajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.(189) The best evidence is for rifaximin 550 mg, thrice daily for 2 weeks.”
BackgroundACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
“001) when both trial results were pooled in the follow-up month (200).”
BackgroundSelf-citationAn irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835
“This and the hypothesis that small intestinal bacterial overgrowth might also contribute to IBS symptomatology(5) have motivated investigation of antibiotics as therapeutic agents in IBS.(6) Large double-blind studies of some antibiotics have shown an improvement (albeit modest, though statistically significant) in IB…”
BackgroundBäckhed, F., Fraser, C. M., Ringel, Y., Sanders, M. E., Sartor, R. B., Sherman, P. M., Versalovic, J., Young, V., & Finlay, B. B. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.10.012 · Cited by 836
“…data have shown that they can also be beneficial in certain disease conditions that do not have established pathogen-associated etiology such as IBD and irritable bowel syndrome (IBS), although the precise mechanism of effect is not completely understood (Khan et al., 2011; Pimentel et al., 2011).”
BackgroundSelf-citationMechanisms and consequences of intestinal dysbiosis
Weiss, G. A., & Hennet, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2509-x · Cited by 775
“Such an eubiotic effect is typical for rifaximin, which contributes to increasing the gut microbial diversity in IBD patients [94] and also improves symptoms of irritable bowel syndrome [95].”
BackgroundMechanick, J. I., Youdim, A., Jones, D. B., Timothy Garvey, W., Hurley, D. L., Molly McMahon, M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.12.010 · Cited by 703
“[388] Pimentel M, Lembo A, Chey WD, et al.”
BackgroundGastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Self-citationAntibiotics as deep modulators of gut microbiota: between good and evil
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016) · Gut · doi:10.1136/gutjnl-2016-312297 · Cited by 625
“107 This large body of evidence led rifaximin to be approved by US Food and Drug Administration for the treat-ment of IBS-D in 2015.”
BackgroundFord, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
“One paper pooled adverse events from two RCTs, meaning that these data were not extractable.(97) As a result, only three RCTs reported adverse events in 817 patients.”
BackgroundResultKelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., Abd, M., Alani, M., Bakow, B., Curran, P., McKenney, J., Tisch, A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0271 · Cited by 613
“Patients with IBS may report improvement in symptoms after a course of antibiotics (21), making it difficult to distinguish diarrheal symptoms related to IBS from those of CDI; some patients who were “cured” by autologous FMT may have been in this category.”
BackgroundBritish Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
“144 In addition, despite this being the rationale for use of non-absorbable antibiotics in IBS, 70 a positive breath test result does not predict response to treatment.”
Petra, A. I., Panagiotidou, S., Hatziagelaki, E., Stewart, J. M., Conti, P., & Theoharides, T. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.002 · Cited by 592
Ford, A. C., Lacy, B. E., & Talley, N. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1607547 · Cited by 587
Pathophysiology of irritable bowel syndrome
Holtmann, G. J., Ford, A. C., & Talley, N. J. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30023-1 · Cited by 590
Konturek, P. C., Brzozowski, T., & Konturek, S. J. (2011) · PubMed · Cited by 818
Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
Saha, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6759 · Cited by 500
Hayati Rezvan, P., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 459
“Results Overall, we identified 103 published articles using MI during the study period (Figure 1) [32-134].”
BackgroundCarroll, I. M., Ringel‐Kulka, T., Siddle, J. P., & Ringel, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01891.x · Cited by 425
“Furthermore, studies show that manipulation of the intestinal microbiota in humans with probiotics or antibiotics may be effective in alleviating IBS symptoms[15-18].”
BackgroundSelf-citationMechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Endocrine Practice · doi:10.4158/ep12437.gl · Cited by 395
Gut bacteria in health and disease.
Quigley, E. M. M. (2013) · Europe PMC (PubMed Central) · Cited by 583
Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome
Moloney, R. D., Johnson, A. C., O'Mahony, S. M., Dinan, T. G., Greenwood‐Van Meerveld, B., & Cryan, J. F. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12490 · Cited by 386
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
“There were four rifaximin RCTs at low risk of bias, assessing 1966 patients [137, 139, 142], and pooled data from these four trial suggested rifaximin was superior to placebo in terms of improving IBS symptoms (NNT = 11; 95% CI = 8 to 21).”
MethodSelf-citationEswaran, S. L., Chey, W. D., Han-Markey, T., Ball, S., & Jackson, K. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.434 · Cited by 383
Self-citationThe mucosal immune system: master regulator of bidirectional gut-brain communications
Powell, N., Walker, M. M., & Talley, N. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.191 · Cited by 379
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Kastl, A. J., Terry, N. A., Wu, G. D., & Albenberg, L. G. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.07.006 · Cited by 358
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334
Self-citationIrritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 331
Chong, P. P., Chin, V. K., Looi, C. Y., Wong, W. F., Madhavan, P., & Yong, V. C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01136 · Cited by 328
Sex-gender differences in irritable bowel syndrome
Kim, Y. S., & Kim, N. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18082 · Cited by 322
“for 2 weeks showed significant improvement in IBS symptoms, bloating, abdominal pain, and loose or watery stools.(92) In a recent phase 3 study of patients (female 68.”
BackgroundKoloski, N. A., Jones, M., & Talley, N. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13738 · Cited by 318
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
Lembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.003 · Cited by 310
“001, pooled data).(15) In addition, a greater percentage of rifaximin-treated than placebo-treated patients reported durable improvement in IBS-D symptoms for at least 10weeks post-treatment (P 1⁄4 .”
BackgroundResultInfluentialSelf-citationThe intestinal microbiota and chronic disorders of the gut
DuPont, A. W., & DuPont, H. L. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.133 · Cited by 307
Peripheral mechanisms in irritable bowel syndrome
Camilleri, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1207068 · Cited by 300
Black, C. J., Thakur, E. R., Houghton, L. A., Quigley, E. M. M., Moayyedi, P., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2020-321191 · Cited by 299
Irritable bowel syndrome: a gut microbiota-related disorder?
Bhattarai, Y., Muniz Pedrogo, D. A., & Kashyap, P. C. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00338.2016 · Cited by 294
Carroll, I. M., Ringel-Kulka, T., Keku, T. O., Chang, Y.-H., Packey, C. D., Sartor, R. B., & Ringel, Y. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00154.2011 · Cited by 292
Self-citationMenees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283
Self-citationGut microbiota and gastrointestinal health: current concepts and future directions
Aziz, Q., Doré, J., Emmanuel, A., Guarner, F., & Quigley, E. M. M. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12046 · Cited by 280
Peripheral Mechanisms in Irritable Bowel Syndrome
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214185 · Cited by 280
Xu, D., Gao, J., Gillilland, M., Wu, X., Song, I., Kao, J. Y., & Owyang, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.026 · Cited by 271
Irritable bowel syndrome: A clinical review
Soares, R. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12144 · Cited by 266
Gatta, L., & Scarpignato, C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13928 · Cited by 266
Fairbrass, K. M., Costantino, S. J., Gracie, D. J., & Ford, A. C. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30300-9 · Cited by 259
Methanogens, Methane and Gastrointestinal Motility
Triantafyllou, K., Chang, C., & Pimentel, M. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2014.20.1.31 · Cited by 254
Self-citationThe intestinal microbiome, probiotics and prebiotics in neurogastroenterology
Saulnier, D. M., Ringel, Y., Heyman, M. B., Foster, J. A., Bercik, P., Shulman, R. J., Versalovic, J., Verdu, E. F., Dinan, T. G., Hecht, G., et al. (2013) · Gut Microbes · doi:10.4161/gmic.22973 · Cited by 248
Self-citationA Clinician's Primer on the Role of the Microbiome in Human Health and Disease
Khanna, S., & Tosh, P. K. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.10.011 · Cited by 227
Irritable Bowel Syndrome, Gut Microbiota and Probiotics
Lee, B. J., & Bak, Y.-T. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.3.252 · Cited by 228
Novel concepts in the pathophysiology and treatment of functional dyspepsia
Wauters, L., Talley, N. J., Walker, M. M., Tack, J., & Vanuytsel, T. (2020) · Gut · doi:10.1136/gutjnl-2019-318536 · Cited by 228
Beneficial modulation of the gut microbiota
Walsh, C. J., Guinane, C. M., O'Toole, P. W., & Cotter, P. D. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.035 · Cited by 274
“Regardless, a bacterial role in IBS onset would seem to be clear, as further evidenced by the disease’s response to antibiotic therapy [33] and differential expression levels of Toll-like receptors in colonic biopsies of patients with IBS [34].”
BackgroundAGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review
Quigley, E. M. M., Murray, J. A., & Pimentel, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.090 · Cited by 220
Self-citationThe influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease
Parekh, P. J., Balart, L. A., & Johnson, D. A. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.16 · Cited by 219
“from the largest randomized control trials to date by Pimental et al.(109) totaling 1,260 patients with IBS (without constipation).”
BackgroundA Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies
Rodiño-Janeiro, B. K., Vicario, M., Alonso-Cotoner, C., Pascua-García, R., & Santos, J. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0673-5 · Cited by 214
“23, depending on the germ involved [15]; randomized placebo-controlled trials with non-absorbable antibiotics such as rifixamin may benefit IBS patients [16]; some pro-/prebiotics can alleviate IBS symptoms, though more evidence is needed [18]; dietary interventions known to modify the intestinal microbiota have also…”
BackgroundThe intestinal microbiota: its role in health and disease
Biedermann, L., & Rogler, G. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-014-2476-2 · Cited by 211
“, the proportion of patients with a relief of global IBS symptoms [147].”
BackgroundStress and visceral pain: From animal models to clinical therapies
Larauche, M., Mulak, A., & Taché, Y. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.04.020 · Cited by 211
The immune system in irritable bowel syndrome
Barbara, G., Cremon, C., Carini, G., Bellacosa, L., Zecchi, L., Giorgio, R. D., Corinaldesi, R., & Stanghellini, V. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.4.349 · Cited by 211
Holvoet, T., Joossens, M., Vázquez-Castellanos, J. F., Christiaens, E., Heyerick, L., Boelens, J., Verhasselt, B., van Vlierberghe, H., De Vos, M., Raes, J., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.07.013 · Cited by 201
Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth
Shah, S. C., Day, L. W., Somsouk, M., & Sewell, J. L. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12479 · Cited by 206
“34 That rifaximin has been shown to be an effective therapy for irritable bowel syndrome patients without constipation further supports the role of SIBO in irritable bowel syndrome.(35) In summary, we identified 10 studies comparing antibiotic therapies for SIBO.”
ResultEvidence-based clinical practice guidelines for irritable bowel syndrome
Fukudo, S., Kaneko, H., Akiho, H., Inamori, M., Endo, Y., Okumura, T., Kanazawa, M., Kamiya, T., Sato, K., Chiba, T., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-1017-0 · Cited by 205
“Comment: In the US and Europe, the utility of non-absorbable, antimicrobial agents in IBS has been investigated in multiple intervention studies, and the efficacy of rifaximin [79–83] and neomycin [83, 84] has been proven in highquality RCTs.”
BackgroundColombel, J.-F., Shin, A., & Gibson, P. R. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.001 · Cited by 203
Ghoshal, U. C., Shukla, R., & Ghoshal, U. (2017) · Gut and Liver · doi:10.5009/gnl16126 · Cited by 204
“Antibiotics While choosing antibiotics, one should consider whether its antibacterial spectrum is broad including aerobes and anaerobes and absorption is poor reducing systemic side effects.108 Though in the past, tetracycline, doxycycline, co-trimoxazole, fluoroquinolones have all been used in the treatment of SIBO,1…”
BackgroundInfluentialParkes, G. C., Rayment, N. B., Hudspith, B. N., Petrovska, L., Lomer, M. C., Brostoff, J., Whelan, K., & Sanderson, J. D. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01803.x · Cited by 200
Diet-microbiota interactions and their implications for healthy living
Jeffery, I., & O'Toole, P. (2013) · Nutrients · doi:10.3390/nu5010234 · Cited by 199
“It is becoming increasingly recognised that low-grade inflammation [67,68] and changes in the gut microbiota are present in a majority of patients, reinforced by observations that probiotic and antibiotic intervention may be effective in reducing the severity of the IBS symptoms [69,70].”
BackgroundFord, A. C., & Talley, N. J. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0379-9 · Cited by 200
Moayyedi, P., Andrews, C. N., MacQueen, G., Korownyk, C., Marsiglio, M., Graff, L., Kvern, B., Lazarescu, A., Liu, L., Paterson, W. G., et al. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy071 · Cited by 150
Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N. (2019) · Gut · doi:10.1136/gutjnl-2017-315136 · Cited by 195
Lembo, A., Sultan, S., Chang, L., Heidelbaugh, J. J., Smalley, W., & Verne, G. N. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.017 · Cited by 192
Self-citationBlack, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Pyleris, E., Giamarellos-Bourboulis, E. J., Tzivras, D., Koussoulas, V., Barbatzas, C., & Pimentel, M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2033-7 · Cited by 194
Self-citationEvidence-based clinical practice guidelines for irritable bowel syndrome 2020
Fukudo, S., Okumura, T., Inamori, M., Okuyama, Y., Kanazawa, M., Kamiya, T., Sato, K., Shiotani, A., Naito, Y., Fujikawa, Y., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-020-01746-z · Cited by 163
Ianiro, G., Eusebi, L. H., Black, C. J., Gasbarrini, A., Cammarota, G., & Ford, A. C. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15330 · Cited by 188
Defrees, D. N., & Bailey, J. (2017) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2017.07.009 · Cited by 188
Irritable bowel syndrome: Emerging paradigm in pathophysiology
Lee, Y. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2456 · Cited by 185
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0470-z · Cited by 181
“[12], and probiotics.”
Garey, K. W., Ghantoji, S. S., Shah, D. N., Habib, M., Arora, V., Jiang, Z.-D., & DuPont, H. L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr377 · Cited by 181
Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview
Holtmann, G., Shah, A., & Morrison, M. (2017) · Digestive Diseases · doi:10.1159/000485409 · Cited by 178
Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome—An Update
Takakura, W., & Pimentel, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00664 · Cited by 148
“Similarly, multiple large randomized controlled trials have shown that rifaximin can improve symptoms in subjects with IBS without constipation (78, 79).”
BackgroundSelf-citationPrantera, C., Lochs, H., Grimaldi, M., Danese, S., Scribano, M. L., & Gionchetti, P. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.032 · Cited by 176
Manipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies
Shanahan, F., & Quigley, E. M. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.050 · Cited by 172
“It therefore might be unrealistic to expect a single agent to cure all symptoms of IBS.”
BackgroundInfluentialDuPont, H. L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12728 · Cited by 171
“The authors noted that, consistent with the behavioural changes, mice receiving the antibiotic mixture also had higher levels of central brain-derived neurotropic factor in the hippocampus and lower levels in the amygdala compared with controls.77 Collins et al. Table 1 | Published randomised, placebo-controlled, clin…”
MethodResultInfluentialMicrobiome and Its Role in Irritable Bowel Syndrome
Pimentel, M., & Lembo, A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06109-5 · Cited by 167
Self-citationThe gut Microbiome in adult and pediatric functional gastrointestinal disorders
Shin, A., Preidis, G. A., Shulman, R., & Kashyap, P. C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.054 · Cited by 163
“Rifaximin has been studied in functional dyspepsia,(146) abdominal bloating, and flatulence,(150) and is approved for treatment of adults with IBS-D.(151) The exact mechanisms by which rifaximin exerts its effects in IBS, however, remain uncertain, with a recent study of patients with nonconstipated IBS showing border…”
BackgroundPathophysiology, Evaluation, and Management of Chronic Watery Diarrhea
Camilleri, M., Sellin, J. H., & Barrett, K. E. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.014 · Cited by 166
Optimization of fecal sample processing for microbiome study — The journey from bathroom to bench
Wu, W.-K., Chen, C.-C., Panyod, S., Chen, R.-A., Wu, M.-S., Sheen, L.-Y., & Chang, S.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.005 · Cited by 162
Moloney, R. D., O’Mahony, S. M., Dinan, T. G., & Cryan, J. F. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00015 · Cited by 161
How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach
Rezaie, A., Pimentel, M., & Rao, S. S. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0482-9 · Cited by 161
Self-citationDysbiosis in gastrointestinal disorders
Chang, C., & Lin, H. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.02.001 · Cited by 158
Dietary and pharmacological treatment of abdominal pain in IBS
Camilleri, M., & Boeckxstaens, G. (2017) · Gut · doi:10.1136/gutjnl-2016-313425 · Cited by 158
Sun, Y., Zhang, M., Chen, C., Gillilland, M., Sun, X., El–Zaatari, M., Huffnagle, G. B., Young, V. B., Zhang, J., Hong, S., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.038 · Cited by 157
The microbiota-gut-brain axis in functional gastrointestinal disorders
De Palma, G., Collins, S. M., & Bercik, P. (2014) · Gut Microbes · doi:10.4161/gmic.29417 · Cited by 157
A Gastroenterologist's Guide to Probiotics
Ciorba, M. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.024 · Cited by 150
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.